VivoSim LabsFRA:4OR 39 PB Ratio is 2.40 as of Jun. 25, 2026, which is 23% above its 10-year median of 1.95. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.13. The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, VivoSim Labs ranks better than 92.13% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), VivoSim Labs's share price is €3.492. VivoSim Labs's Book Value per Share for the quarter that ended in Dec. 2025 was €1.45. Hence, VivoSim Labs's PB Ratio of today is 2.40.
The historical rank and industry rank for VivoSim Labs's PB Ratio or its related term are showing as below:
FRA:4OR'
s PB Ratio Range Over the Past 10 Years
Min: 0.26 Med: 1.95 Max: 30.59
Current: 0.66
During the past 13 years, VivoSim Labs's highest PB Ratio was 30.59. The lowest was 0.26. And the median was 1.95.
FRA:4OR's PB Ratio is ranked better than 92.13% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:4OR: 0.66
During the past 12 months, VivoSim Labs's average Book Value Per Share Growth Rate was 567.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -49.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -42.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -29.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of VivoSim Labs was -1.30% per year. The lowest was -57.10% per year. And the median was -24.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
VivoSim Labs PB Ratio Related Terms
VivoSim Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VivoSim Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
VivoSim Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
VivoSim Labs (FRA:4OR) has a PB Ratio of 2.40 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on VivoSim Labs and its competitors. This is 23% above median its historical median of 1.95. Over the past decade, VivoSim Labs' PB Ratio has ranged from 0.26 to 30.59. According to the industry distribution chart, VivoSim Labs ranks #97 out of 1233 companies in the Biotechnology industry, placing it in the top 7.9%.
Is VivoSim Labs' PB Ratio too high?
VivoSim Labs' current PB Ratio of 2.40 is 23% above median its 10-year median of 1.95. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 30.59. The Biotechnology industry median PB Ratio is 2.80. VivoSim Labs' value of 2.40 is 14.3% below this industry median. Based on the distribution chart, VivoSim Labs ranks #97 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' PB Ratio compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #97 out of 1233 companies for PB Ratio. This places VivoSim Labs in the top 8% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. VivoSim Labs' value of 2.40 is 14.3% below this benchmark. Historically, VivoSim Labs' own PB Ratio has ranged from 0.26 to 30.59 over the past decade. While the company's 10-year median is 1.95 vs. the industry median of 2.80, VivoSim Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current PB Ratio of 2.40 is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current PB Ratio is 2.40, which is 23% above median its own 10-year median of 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current PB Ratio of 2.40. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current PB Ratio is 2.40, which is 23% above median its 10-year median of 1.95 and 14.3% below the Biotechnology industry median of 2.80. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current PB Ratio is 2.40 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.
Key valuation signals for FRA:4OR:
PB Ratio: 2.40 (23% above median its 10-year median of 1.95)
GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
Industry Position: 14.3% below the Biotechnology median (#97 of 1233)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
